Many people, including pro football players, are first introduced to addictive opioid painkillers after an injury Recognizing ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Learn about pain management options during root canal therapy, including anesthesia, sedation, and post-treatment care, for a comfortable dental experience.

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.

A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...

This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.